<DOC>
	<DOC>NCT02674984</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of combination probiotic BB-12 with LGG in healthy children with autism spectrum disorder aged 6-13 years. Subjects will be randomized to BB-12 with LGG orally (LGG dose: 10^9 c.f.u.'s; BB-12: 10^9) for a total of 28 doses or placebo (maltodextrin) at 2:1 ratio. The time on study treatment is 28 days, and the target sample size is 45 individuals (i.e., 30 in the treatment arm and 15 in the placebo arm).</brief_summary>
	<brief_title>Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<criteria>Healthy children with autism spectrum disorders (6 13 years old) with gastrointestinal symptoms but no other recognized illness will be enrolled in this study. There will be no selection on the basis of age, race, or gender. Pregnancy or breastfeeding Subjects taking immunosuppressive medications, including oral corticosteroids A history of positive result of HIV, Hepatitis B, and/or Hepatitis C test Abnormal lab test results (Section 5.2) Gastrointestinal diseases such as celiac disease, inflammatory bowel disease Subjects with an allergy to antibiotics Presence of fever or a preexisting adverse event monitored in the study Use of probiotics in the last 90 days Acute diarrheal illness within the past 30 days Recent (within 2 weeks) or current use of oral antibiotics /antifungals Current use of oral laxatives Subjects with implanted prosthetic devices including prosthetic heart valves We will require that subject not take any other probioticcontaining products, including yogurt supplemented with probiotics during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>